Law360, New York (April 2, 2008, 12:00 AM EDT) -- Merck & Co. Inc. has taken its frustrations over multiple subpoenas from generic-drug maker Ranbaxy Pharmaceuticals Inc. to a judge, claiming that the requests for information on Merck's blood pressure drug Enapren amounted to an international fact-gathering expedition.
In a third-party motion filed Monday, Merck asked the U.S. District Court for the District of New Jersey to quash a recent subpoena for information that Ranbaxy claimed it needed in its ongoing patent litigation with Pfizer Inc. in that court.
Merck said that it had been bombarded...
Merck Seeks To Quash Ranbaxy's Subpoenas
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
